Keros Therapeutics, Inc. (KROS)

Keros Therapeutics' stock experienced a 77.42% decline between October 18, 2024, and October 17, 2025. The company announced a plan to return $375 million in excess capital to shareholders, including a cash tender offer to repurchase up to $194.4 million of its common stock. Pontifax Management 4 G.P. sold 4,787,331 shares for approximately $84.98 million, and Keros agreed to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital. The company reported a quarterly earnings per share of ($0.76), surpassing analyst expectations, but revenues were significantly below forecasts. Analysts have a mixed view on KROS, with a consensus "Hold" rating and a target price of $30.00. Keros officially abandoned its cibotercept program and collected a $10 million development milestone in July 2025 when the first patient in Takeda's Phase 3 trial for MDS (RENEW) was dosed for elritercept.

The provided information does not contain specific details regarding demand seasonality for Keros Therapeutics, Inc.'s products and services. Demand for its products would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than traditional seasonal patterns. The company's current focus is on clinical trials and development rather than commercial sales of established products.

Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for disorders linked to dysfunctional TGF-β protein signaling. The company operates in the Health Care sector, specifically within the Biotechnology: Pharmaceutical Preparations industry. Its lead product candidate, KER-050 (elritercept), is being developed for cytopenias in patients with myelodysplastic syndromes (MDS) and myelofibrosis and has been out-licensed to Takeda Pharmaceutical Company Limited. KER-012 (cibotercept) was in Phase II clinical trials for pulmonary arterial hypertension and cardiovascular disorders, but the program has been abandoned. KER-065 is in Phase I clinical trials for neuromuscular diseases, initially focusing on Duchenne muscular dystrophy (DMD) and has received U.S. FDA Orphan Drug Designation for DMD.

Keros Therapeutics, Inc. primarily develops and commercializes its novel therapeutics for patients in the United States and is headquartered in Lexington, Massachusetts.

Information directly detailing Keros Therapeutics' brand reputation in the past year is not explicitly available. The company has a consensus "Hold" rating from analysts, with a mix of recommendations, suggesting a neutral to cautious view. The significant stock price decline could negatively impact investor confidence. The decision to abandon the cibotercept program might be viewed as a setback, while the capital return program could be perceived positively. Receiving FDA Orphan Drug Designation for KER-065 for Duchenne muscular dystrophy is a positive development.

The ownership structure of Keros Therapeutics (KROS) stock includes institutional, retail, and individual investors. Keros Therapeutics has 305 institutional owners and shareholders holding a total of 40,134,055 shares. Alon Lazarus is the largest individual shareholder, owning 2.04 million shares, representing 5.01% of the company, and insiders collectively own approximately 28.20% of the company's stock.